AmpliPhi Biosciences Corp APHB:NYSE American
AmpliPhi to Collaborate with Western Sydney Local Health District and Westmead Institute for Medical Research on Expanded Access for Investigational Bacteriophage Therapeutics AB-SA01 and AB-PA01
BusinessWire
4:10 PM ET
AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced a collaboration with the Western Sydney Local Health District and the Westmead Institute for Medical Research, based in Sydney, Australia. The agreement covers compassionate use treatment of patients with severe Staphylococcus aureus and Pseudomonas aeruginosa infections with AmpliPhi's investigational bacteriophage therapeutics AB-SA01 and AB-PA01.
To date, several critically ill patients have received AB-SA01 or AB-PA01 at the Westmead Hospital, under the Australian Therapeutic Goods Administr ation's Special Access Scheme guidelines. In January, AmpliPhi announced positive interim results from the first patients treated under its single-patient expanded access program, including patients treated at the Westmead Hospital. This new agreement will expand and is expected to accelerate the collaboration to supply AB-SA01 and AB-PA01 for additional patients with serious and life-threatening infections, who do not respond to antibiotics, while collecting clinical and microbiological data.
"I'm delighted to expand the partnership with AmpliPhi and make these investigational bacteriophage treatments available for critically ill patients who have few or no other treatment options," said Dr. Jonathan Iredell, Senior Staff Infectious Diseases Physician and Clinical Microbiologist at the Westmead Hospital, Professor of Medicine and Microbiology at the University of Sydney and Westmead Institute of Medical Research, and the Principal Investigator. "The promising clinical results I have observed to-date support the potential of bacteriophage therapeutics to be a safe and potent adjunct treatment for serious bacterial infections."
"We are pleased to strengthen the relationship with our partners at the Westmead
